Earnings Feed
Start Free
Cytek Biosciences, Inc.·4

Mar 12, 4:38 PM ET

Jiang Wenbin 4

Research Summary

AI-generated summary

Updated

Cytek (CTKB) CEO Jiang Wenbin Receives RSUs and Exercises/Converts Derivatives

What Happened
Jiang Wenbin, President & CEO and a director of Cytek Biosciences (CTKB), had multiple equity events reported for March 10, 2026. He was granted/awarded two RSU awards totaling 1,400,952 RSU units (485,545 and 915,407 RSUs). In addition, three derivative exercises/conversions occurred for 15,708; 29,467; and 38,669 shares (total = 83,844). To satisfy tax withholding obligations arising from vesting/conversion, 20,988 shares were withheld/surrendered to the company at $4.23 per share, totaling $88,780. No open‑market sale proceeds to Jiang are reported — the only disposals reflect shares withheld for taxes or conversion mechanics.

Key Details

  • Transaction date: March 10, 2026; Form 4 filed March 12, 2026 (timely).
  • Awards granted: 485,545 RSUs and 915,407 RSUs (total 1,400,952 RSUs) recorded as acquisitions (derivative awards) at $0.00.
  • Derivative exercises/conversions: 15,708; 29,467; and 38,669 shares (total 83,844). Some conversion entries are recorded as disposals at $0.00, reflecting conversion/transfer rather than a market sale.
  • Tax withholding: 3,825 + 7,747 + 9,416 = 20,988 shares surrendered to issuer to cover withholding, at $4.23/share = $88,780. (Transaction code F = tax/exercise payment.)
  • Vesting notes: awards vest over four years under multiple schedules (see footnotes F3–F7); some awards include vesting events on March 10, 2026.
  • Shares owned after transaction: not specified in the information provided.

Context and plain English explanation:

  • These filings show RSU grants and the conversion/vesting of derivative awards, not open‑market purchases or sales. RSUs convert to common stock when they vest (no cash purchase required); the company commonly withholds some shares to cover taxes (the withheld shares are the only shares shown as “disposed”).
  • Transaction codes: A = award/grant, M = exercise/conversion of derivative, F = payment of exercise price or tax withholding.
  • This activity is routine compensation/vesting and does not necessarily indicate insider sentiment for open‑market buying or selling.